Ongoing Results From a Dose Expansion Cohort of CYT-0851 in Combination With Capecitabine in Advanced Platinum-Resistant Ovarian Cancer Show Promising Clinical Activity and Generally Well Tolerated Safety Profile marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
Cyteir Therapeutics, Inc. presented ongoing results from a dose expansion cohort in its Phase 1 combination study of CYT-0851 with capecitabine in patients with platinum-refractory or -resistant.
Liga de Expansión MX Resultados Jornada 2 del Clausura 2021 mediotiempo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mediotiempo.com Daily Mail and Mail on Sunday newspapers.